|1.||WO||WO/2013/181686 - ENDOLUMINAL VACUUM THERAPY DEVICE||12.12.2013||
|PCT/AU2013/000262||KLEINER, Daniel Eduard||KLEINER, Daniel Eduard|
There are provided devices for applying negative pressure to a wound in an endoluminal surface of a patient to facilitate healing of the wound and methods for use of the devices. The device (69, 94, 134, 140, 156, 164) comprises a flexible porous element with an outer face defined between opposite proximal and distal ends of the porous element. A suction tube (30) for being connected to a suction source externally of the patient's body is in fluid communication with the porous element (14) to apply the negative pressure to the wound via the outer face of the porous element. In some embodiments, the porous element has a longtitudinal passageway (16) for passage of bodily substances of the patient along the lumen defining the endoluminal surface through the porous element. In such embodiments, the device may also have at least one absorbent element (70, 80) for absorbing the bodily substances and which is disposed forwardly or rearwardly of the porous element (14). Embodiments of the device may also include a drainage tube (22) for collection and drainage of bodily substances from the patient and which is received in the longtitudinal passageway (16) of the porous element. In other embodiments, the porous element can be in the form of a mat wrapped around a feeding or other insertion tube. The porous element of a device embodied by the invention may also include one or more irrigation channels (85, 86) for delivery of an irrigation fluid into or though, the porous element. The porous element and/or absorbent element(s) may be sponge(s).
|2.||WO||WO/2013/181687 - A METHOD AND A SYSTEM FOR DETERMINING A VELOCITY OF A RELATIVE MOVEMENT BETWEEN AN OBJECT AND A FLUIDAL MEDIUM||12.12.2013||
|PCT/AU2013/000567||NEWSOUTH INNOVATIONS PTY LIMITED||O'BYRNE, Sean Brendan|
The present disclosure provides a method and a system for determining a velocity of a relative movement between a system for determining the velocity and a fluidal medium. The method comprises directing at least two light beams through at least a portion of the fluidal medium using the system such that a portion of light of each light beam is absorbed by the fluidal medium. Further, the method comprises detecting first and second spectral intensity profiles of the at least two light beams to detect the light absorption. The method also comprises determining a difference profile associated with spectral intensity differences between a first and a second spectral intensity profile; and integrating an absolute value function of the difference profile to determine the velocity. The at least two light beams are directed such that the first and second spectral intensity profiles each have a different spectral position. The system has components that are arranged to allow operation of the above-described method.
|3.||WO||WO/2013/181688 - SLAM LATCH||12.12.2013||
|PCT/AU2013/000577||OLSSON, Ashley Dean||OLSSON, Ashley Dean|
This invention relates to a slam latch, and to methods of operating a gate/panel using the slam latch. The slam latch comprises (i) a mounting body; (ii) a latch bolt having a longitudinal axis and being mounted relative to the mounting body for axial movement relative to the mounting body between a locking position and an unlocking position, said latch bolt having a keeper-engaging end extending from the mounting body; and (iii) a keeper adapted to receive the keeper-engaging end of the latch bolt when the latch bolt is in the locking position.
|4.||WO||WO/2013/181689 - IMPROVED COLD RUNNER BLOCK||12.12.2013||
|PCT/AU2013/000578||ROMAR ENGINEERING PTY LTD||FURBY, David|
The present invention provides a cold runner block (100) for use with one or more injector nozzles (120) in an injection moulding system for dispensing a flowable material, including a block (100) which has at least one injector nozzle mount (110) that extends away from the block (100) to receive at least one of the injector nozzles (120), an interior space of each mount defining an injection cavity (112) that is adapted to receive an injection nozzle (120), the block (100) having formed in it a coolant gallery (105,106,109) that passes into the injection cavity (112).
|5.||WO||WO/2013/181690 - SYNCHRONISATION OF A SYSTEM OF DISTRIBUTED COMPUTERS||12.12.2013||
|PCT/AU2013/000579||CHRONOLOGIC PTY LTD||FOSTER, Peter Graham|
A method of determining a propagation time of signals from a USB Host Controller to an attached USB device is disclosed. In an embodiment, the method comprises: said USB device sending a message or data packet to said USB Host Controller; said USB device starting a local timer upon transmission of said message or data packet; said USB Host Controller responding to said message or data packet by issuing a handshake token; and said USB device stopping said local timer on receipt of said handshake token; wherein said local timer value represents twice the propagation time of signals from said USB Host Controller to said USB device.
|6.||WO||WO/2013/181691 - A METHOD OF TREATMENT AND COMPOSITIONS USEFUL THEREFOR, SCREENING AND PROGNOSTIC AGENTS AND USES THEREFOR||12.12.2013||
|PCT/AU2013/000582||THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD||PALMER, Clovis|
Disclosed is an assay to stratify a subject as progressing or not-progressing with respect to HIV disease progression, the assay comprising determining the level or activity of CD4+ T cell Glut1 in a biological sample from the HIV infected subject, wherein the level or activity of CD4+ T cell Glut1 in the subject relative to a control identifies the subject as progressing or not progressing also, a method of reducing T cell immune activation and/or inflammation in a subject in need thereof comprising administering to the subject an effective amount of an anti-glycolytic agent or Glut1 antagonist for a time and under conditions sufficient to effectively suppress markers of T cell immune activation or inflammation, or normalise Glut1 levels, glucose uptake or glycolysis in CD4+ T cells in the subject. Methods of reducing HIV infection and reducing HIV associated pathogenesis are also provided. The CD4+ T cell Glut1 antagonist is illustrated using an PI3K-mTOR inhibitor. The PI3K-mTOR inhibitor is a PI3Kγ inhibitor and/or an mTORC1 inhibitor. Combinations and effective dosages of PI3Kγ -mTORC1 inhibitors are also provided.
|7.||WO||WO/2013/181692 - STICK MIXER DRIVEN FOOD PROCESSOR||12.12.2013||
|PCT/AU2013/000585||BREVILLE PTY LIMITED||RYAN, Garth|
A food processing lid is used with a cooperating bowl and a stick mixer handle. The lid has a feed tube and a recess for receiving a removeable gearbox that is driven by a stick mixer.
|8.||WO||WO/2013/181693 - INTEGRATED CARBON CAPTURE AND GAS TO LIQUIDS SYSTEM||12.12.2013||
|PCT/AU2013/000586||LINC ENERGY LTD||IYER, Raj|
A gas to liquids process is described wherein carbon dioxide is captured and used within the gas to liquids process.
|9.||WO||WO/2013/181694 - COMPOSITIONS AND METHODS FOR TREATING CROHN'S DISEASE AND RELATED CONDITIONS AND INFECTIONS||12.12.2013||
|PCT/AU2013/000587||AGRAWAL, Gaurav||AGRAWAL, Gaurav|
In alternative embodiments, the invention provides a "triple combination" therapy for treating, ameliorating and preventing Crohn's Disease (or Crohn syndrome, terminal or distal ileitis or regional enteritis) or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor; and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes Crohn's Disease or paratuberculosis infection in mammals. In alternative embodiments, the methods and uses of the invention for treating, ameliorating and preventing Crohn's Disease and complications of Crohn's Disease, or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, comprises administration to an individual (human or mammal) in need thereof: (1) an anti - TNFα composition, or a composition capable of down-modulating TNFα activity; (2) a Hyperbaric Oxygen Treatment, or HBOT; and (3) an anti- Mycobacterium avium sub species paratuberculosis (MAP) (an anti-MAP) agent, composition or therapy.
|10.||WO||WO/2013/181695 - BIOMETRIC VERIFICATION||12.12.2013||
|PCT/AU2013/000588||NATIONAL ICT AUSTRALIA LIMITED||MAU, Sandra|
A method of verifying an input biometric identifier against a reference biometric identifier is disclosed in this specification. The method comprises evaluating the input biometric identifier relative to a group (the 'cohort') to improve verification accuracy. Up to three matching scores are used to determine a verification probability for the input biometric identifier. The three matching scores measure the similarity of the input biometric identifier to the biometric identifiers of the cohort, the similarity of the reference biometric identifier to the biometric identifiers of the cohort and the similarity of the input biometric identifier to the reference biometric identifier.